FDA advisors quit after approval of Alzheimer's medicine

On Monday, US authorities defied an external panel by approving Biogen's Alzheimer's treatment. Now, several of the participants are stepping down.

Three members of an outside panel that advises the US Food and Drug Administration (FDA) have quit over the past few days.

This is in protest over the decision made by the authority to approve Aduhelm, an Alzheimer's drug developed by Biogen.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs